Compare GE & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GE | PFE |
|---|---|---|
| Founded | 1892 | 1849 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.8B | 155.0B |
| IPO Year | 2008 | 2013 |
| Metric | GE | PFE |
|---|---|---|
| Price | $324.32 | $27.31 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 12 |
| Target Price | ★ $337.50 | $27.83 |
| AVG Volume (30 Days) | 4.1M | ★ 31.7M |
| Earning Date | 04-22-2026 | 05-04-2026 |
| Dividend Yield | 0.58% | ★ 6.33% |
| EPS Growth | ★ 35.89 | N/A |
| EPS | ★ 8.14 | 1.36 |
| Revenue | $45,855,000,000.00 | ★ $62,579,000,000.00 |
| Revenue This Year | $8.18 | N/A |
| Revenue Next Year | $10.10 | N/A |
| P/E Ratio | $40.16 | ★ $19.93 |
| Revenue Growth | ★ 18.48 | N/A |
| 52 Week Low | $159.36 | $20.92 |
| 52 Week High | $348.48 | $27.94 |
| Indicator | GE | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 47.86 | 55.93 |
| Support Level | $288.37 | $24.99 |
| Resistance Level | $332.79 | $27.67 |
| Average True Range (ATR) | 9.40 | 0.51 |
| MACD | -2.56 | -0.06 |
| Stochastic Oscillator | 33.94 | 75.51 |
GE Aerospace is the global leader in designing, manufacturing, and servicing commercial aircraft turbine engines, along with partner Safran in their CFM joint venture. With its massive global installed base of nearly 80,000 commercial and military engines, GE Aerospace earns most of its profits on recurring service revenue of that equipment, which operates for decades. GE Aerospace is the remaining core business of the company formed in 1892 with historical ties to American inventor Thomas Edison; that company became a storied conglomerate with peak revenue of $130 billion in 2000 until GE spun off its appliance, finance, healthcare, and wind and power businesses between 2016 and 2024.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.